https://www.sciencedaily.com/news/health_medicine/herpes/ Herpes news. Read the latest research on the herpes virus, including new treatment options. en-us Mon, 09 Mar 2026 00:32:54 EDT Mon, 09 Mar 2026 00:32:54 EDT 60 https://www.sciencedaily.com/images/scidaily-logo-rss.png https://www.sciencedaily.com/news/health_medicine/herpes/ For more science news, visit ScienceDaily. https://www.sciencedaily.com/releases/2026/03/260306224220.htm Scientists have revealed how the body’s microscopic cold sensor, TRPM8, detects both chilly temperatures and the cooling effect of menthol. The discovery finally shows how the sensation of “cool” works at the molecular level—and could inspire new treatments for pain and eye disorders. Sun, 08 Mar 2026 01:31:56 EST https://www.sciencedaily.com/releases/2026/03/260306224220.htm https://www.sciencedaily.com/releases/2026/02/260222092258.htm Scientists at Stanford Medicine have unveiled a bold new kind of “universal” vaccine that could one day protect against everything from COVID-19 and the flu to bacterial pneumonia and even common allergens. Instead of targeting a specific virus or bacterium, the nasal spray vaccine supercharges the lungs’ own immune defenses, keeping them on high alert for months. In mice, it slashed viral levels, prevented severe illness, and even blocked allergic reactions. Mon, 23 Feb 2026 08:45:18 EST https://www.sciencedaily.com/releases/2026/02/260222092258.htm https://www.sciencedaily.com/releases/2026/02/260204114343.htm As bird flu continues to circulate in animals and spill over into humans, researchers are racing to stop it before it adapts to spread widely between people. A new nasal spray vaccine showed strong protection against H5N1 in animal tests, outperforming traditional flu shots. Because it targets the nose and lungs, it may prevent infection at the earliest stage. Wed, 04 Feb 2026 11:43:43 EST https://www.sciencedaily.com/releases/2026/02/260204114343.htm https://www.sciencedaily.com/releases/2026/01/260106224628.htm Researchers have reconstructed ancient herpesvirus genomes from Iron Age and medieval Europeans, revealing that HHV-6 has been infecting humans for at least 2,500 years. Some people inherited the virus directly in their DNA, passing it down across generations. The study shows that these viruses evolved alongside humans—and that one strain eventually lost its ability to integrate into our chromosomes. It’s the first time this long, intimate relationship has been proven with ancient genetic evidence. Wed, 07 Jan 2026 07:07:41 EST https://www.sciencedaily.com/releases/2026/01/260106224628.htm https://www.sciencedaily.com/releases/2025/12/251203004721.htm A unique vaccine rollout in Wales gave researchers an accidental natural experiment that revealed a striking reduction in dementia among seniors who received the shingles vaccine. The protective effect held steady across multiple analyses and was even stronger in women. Evidence also suggests benefits for people who already have dementia, hinting at a therapeutic effect. Wed, 03 Dec 2025 10:22:27 EST https://www.sciencedaily.com/releases/2025/12/251203004721.htm https://www.sciencedaily.com/releases/2025/10/251027224837.htm Researchers found that COVID-19 mRNA vaccines significantly increased survival in lung and skin cancer patients undergoing immunotherapy. The vaccine appears to prime the immune system in a powerful, nonspecific way, enhancing cancer treatment outcomes. If confirmed, the discovery could lead to a universal cancer vaccine and transform oncology care. Tue, 28 Oct 2025 09:47:26 EDT https://www.sciencedaily.com/releases/2025/10/251027224837.htm https://www.sciencedaily.com/releases/2025/10/251019120503.htm A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy lived dramatically longer than those who didn’t. Researchers from the University of Florida and MD Anderson Cancer Center discovered that the vaccine’s immune-activating properties may boost cancer-fighting responses, acting like a nonspecific “flare” that reawakens the immune system. Sun, 19 Oct 2025 12:43:31 EDT https://www.sciencedaily.com/releases/2025/10/251019120503.htm https://www.sciencedaily.com/releases/2025/08/250818102951.htm A breakthrough mRNA cancer vaccine has shown the ability to supercharge the effects of immunotherapy in mice, sparking hope for a universal “off-the-shelf” treatment that could fight multiple cancers. Unlike traditional vaccines designed to target specific tumor proteins, this approach simply revs up the immune system as if it were fighting a virus. The results were dramatic—when paired with checkpoint inhibitors, tumors shrank, and in some cases, the vaccine alone wiped them out. Tue, 19 Aug 2025 02:22:25 EDT https://www.sciencedaily.com/releases/2025/08/250818102951.htm https://www.sciencedaily.com/releases/2025/08/250803011820.htm Scientists have discovered that flossing between your teeth could one day help vaccinate you. By targeting a uniquely permeable gum tissue called the junctional epithelium, this new method stimulates immunity right where many infections enter: the mouth, nose, and lungs. Using dental floss on mice to apply a flu vaccine triggered a robust immune response—better than existing oral approaches and comparable to nasal vaccines, but without the risks. It even worked with mRNA and protein-based vaccines. Sun, 03 Aug 2025 03:57:21 EDT https://www.sciencedaily.com/releases/2025/08/250803011820.htm https://www.sciencedaily.com/releases/2025/07/250720034025.htm A new UK study shows that vaccinating pregnant women against RSV has led to a staggering 72% drop in hospitalizations of newborns with severe lung infections. By passing virus-fighting antibodies to their babies, vaccinated mothers are helping shield infants during their most vulnerable early months. Mon, 21 Jul 2025 08:38:35 EDT https://www.sciencedaily.com/releases/2025/07/250720034025.htm https://www.sciencedaily.com/releases/2025/06/250620031207.htm Cold sore-causing HSV-1 doesn't just hijack cells it reconfigures the entire architecture of our DNA to aid its invasion. Researchers discovered that it actively reshapes the 3D structure of the human genome within hours of infection, using host enzymes like topoisomerase I to gain access to crucial genetic machinery. Stunningly, blocking this single enzyme shuts the virus down completely. Fri, 20 Jun 2025 03:12:07 EDT https://www.sciencedaily.com/releases/2025/06/250620031207.htm https://www.sciencedaily.com/releases/2025/05/250515145628.htm A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional approaches haven't worked -- largely because HIV mutates rapidly and hides key parts of itself from the immune system. Now, a new study combining data from two separate phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV, and, in one trial, further advance them -- a key step toward a long-sought goal in vaccine development. Thu, 15 May 2025 14:56:28 EDT https://www.sciencedaily.com/releases/2025/05/250515145628.htm https://www.sciencedaily.com/releases/2025/05/250515141843.htm MIT scientists have designed self-boosting vaccines that release doses over time from a single injection. This breakthrough could make multi-shot vaccines one-and-done, protecting children in even the most remote corners of the world. Thu, 15 May 2025 14:18:43 EDT https://www.sciencedaily.com/releases/2025/05/250515141843.htm https://www.sciencedaily.com/releases/2025/05/250508112443.htm The recent global monkeypox (mpox) outbreak, with a new and aggressive variant, has underscored the dire need for safe, broadly effective, and accessible vaccines. The LC16m8 vaccine, an attenuated vaccinia virus strain originally developed for smallpox, is a promising option for countering the mpox virus. Exploring this potential further, researchers employed a cross-species immunological analysis to provide new insights into LC16m8's immunogenicity and safety against mpox. The recent global monkeypox (mpox) outbreak, with a new and aggressive variant, has underscored the dire need for safe, broadly effective, and accessible vaccines. The LC16m8 vaccine, an attenuated vaccinia virus strain originally developed for smallpox, is a promising option for countering the mpox virus. Exploring this potential further, researchers employed a cross-species immunological analysis to provide new insights into LC16m8's immunogenicity and safety against mpox. Thu, 08 May 2025 11:24:43 EDT https://www.sciencedaily.com/releases/2025/05/250508112443.htm https://www.sciencedaily.com/releases/2025/05/250505204912.htm People who are given a vaccine for shingles have a 23% lower risk of cardiovascular events, including stroke, heart failure, and coronary heart disease, according to a recent study of more than a million people. The protective effect of the vaccine lasts for up to eight years and is particularly pronounced for men, people under the age of 60 and those with unhealthy lifestyles. Mon, 05 May 2025 20:49:12 EDT https://www.sciencedaily.com/releases/2025/05/250505204912.htm https://www.sciencedaily.com/releases/2025/05/250501163954.htm Urgent action must be taken to reduce the ever-rising number of people killed by extreme temperatures in India, say the authors of a new 19-year study which found that 20,000 people died from heatstroke in the last two decades. Cold exposure claimed another 15,000 lives. Thu, 01 May 2025 16:39:54 EDT https://www.sciencedaily.com/releases/2025/05/250501163954.htm https://www.sciencedaily.com/releases/2025/04/250423111753.htm New multidisciplinary research shows that the brain forms memories of cold experiences and uses them to control our metabolism. The study shows that cold memories form in the brain -- and map out how they subsequently drive thermoregulation. The discovery may have important applications in therapies designed to treat a range of disorders -- from obesity to cancer -- in which thermoregulation and metabolism (or a lack of control in this area) plays a role, as well as opening the door to more fundamental research, which could help us better understand how memories impact our behavior and emotions. Wed, 23 Apr 2025 11:17:53 EDT https://www.sciencedaily.com/releases/2025/04/250423111753.htm https://www.sciencedaily.com/releases/2025/04/250417145009.htm A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as 2.3.4.4b, which has caused widespread outbreaks in wild birds and poultry and other mammals. The vaccine is step toward more potent, versatile and easy-to-produce vaccines that public health officials believe will be needed to counteract evolving bird flu strains that grow resistant to existing vaccines. Thu, 17 Apr 2025 14:50:09 EDT https://www.sciencedaily.com/releases/2025/04/250417145009.htm https://www.sciencedaily.com/releases/2025/04/250408121657.htm Researchers have shown that differences in the entire rotavirus genome -- not just its two surface proteins -- affect how well vaccines work, helping to explain why some strains are more likely to infect vaccinated individuals. Tue, 08 Apr 2025 12:16:57 EDT https://www.sciencedaily.com/releases/2025/04/250408121657.htm https://www.sciencedaily.com/releases/2025/04/250402122149.htm A unique vaccination rollout in Wales offered researchers a natural experiment: some older adults qualified for the shingles vaccine, while others just missed the cutoff. The results were striking — those who got the shot had a 20% lower risk of developing dementia within seven years. This breakthrough hints that viruses lurking in the nervous system may contribute to dementia and that prevention could be simpler than anyone imagined. Wed, 02 Apr 2025 12:21:49 EDT https://www.sciencedaily.com/releases/2025/04/250402122149.htm https://www.sciencedaily.com/releases/2025/03/250325120154.htm Early animal studies show that a single vaccine could protect the recipient from different variants of the coronaviruses that cause COVID-19, the flu and the common cold. In addition to creating antibodies that target a specific region of the spike protein that doesn't mutate, the vaccine removes the sugar coat from the virus that allows it to hide in the body. Tue, 25 Mar 2025 12:01:54 EDT https://www.sciencedaily.com/releases/2025/03/250325120154.htm https://www.sciencedaily.com/releases/2025/03/250319143643.htm A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, and people with HIV in particular, should therefore receive the second dose of the vaccine as recommended. Wed, 19 Mar 2025 14:36:43 EDT https://www.sciencedaily.com/releases/2025/03/250319143643.htm https://www.sciencedaily.com/releases/2025/03/250312134635.htm Researchers helped conduct an important new global health study that found a vaccine that protects against five strains of meningitis prevalent in sub-Saharan Africa is safe and effective for use in young children beginning at 9 months of age. This study provided evidence that formed the basis for the World Health Organization's (WHO) decision last year to recommend the pentavalent Men5CV meningitis vaccine for infants ages 9 months and older. Wed, 12 Mar 2025 13:46:35 EDT https://www.sciencedaily.com/releases/2025/03/250312134635.htm https://www.sciencedaily.com/releases/2025/03/250311122707.htm A more affordable, lower-risk polio vaccine is on the horizon, research has found. Tue, 11 Mar 2025 12:27:07 EDT https://www.sciencedaily.com/releases/2025/03/250311122707.htm https://www.sciencedaily.com/releases/2025/03/250310131647.htm A study finds that herpes infection through the nose can lead to anxiety, motor impairment and cognitive issues. The research shows that by exploiting a cellular enzyme, the virus can produce behavioral symptoms. The finding emphasizes the need for prevention and treatment of a virus carried by billions of people worldwide. Mon, 10 Mar 2025 13:16:47 EDT https://www.sciencedaily.com/releases/2025/03/250310131647.htm https://www.sciencedaily.com/releases/2025/03/250306121242.htm Researchers have discovered how antibodies help to protect against contagious bacterial infections caused by Strep A, including strep throat. And the findings are already contributing to efforts to accelerate the development of a Strep A vaccine. Thu, 06 Mar 2025 12:12:42 EST https://www.sciencedaily.com/releases/2025/03/250306121242.htm https://www.sciencedaily.com/releases/2025/03/250305164340.htm Scientists have discovered a strategy to fight back against norovirus, a leading cause of gastroenteritis worldwide. Their new study identifies powerful antibodies capable of neutralizing a wide range of norovirus strains. The finding could lead to the design of broadly effective norovirus vaccine, as well as the development of new therapeutic antibodies for the treatment of norovirus-associated gastroenteritis. Wed, 05 Mar 2025 16:43:40 EST https://www.sciencedaily.com/releases/2025/03/250305164340.htm https://www.sciencedaily.com/releases/2025/03/250305135134.htm A live-attenuated tuberculosis (TB) vaccine candidate in development elicits a much more balanced and effective immune response compared to the existing vaccine used across much of the world, according to preclinical research. Wed, 05 Mar 2025 13:51:34 EST https://www.sciencedaily.com/releases/2025/03/250305135134.htm https://www.sciencedaily.com/releases/2025/02/250228113958.htm Scientists have a new target to prevent cold sores -- and genital herpes flare-ups caused by the same virus -- after researchers discovered an unexpected way the herpes virus re-activates in the body. Fri, 28 Feb 2025 11:39:58 EST https://www.sciencedaily.com/releases/2025/02/250228113958.htm https://www.sciencedaily.com/releases/2025/02/250220123051.htm A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials. Thu, 20 Feb 2025 12:30:51 EST https://www.sciencedaily.com/releases/2025/02/250220123051.htm https://www.sciencedaily.com/releases/2025/02/250205130931.htm Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine. Wed, 05 Feb 2025 13:09:31 EST https://www.sciencedaily.com/releases/2025/02/250205130931.htm https://www.sciencedaily.com/releases/2025/01/250131110704.htm In a comprehensive systematic review and meta-analysis, researchers have taken a deep dive into the effects of cold-water immersion on health and wellbeing. Analyzing data from 11 studies with 3177 participants, researchers found that cold-water immersion may lower stress, improve sleep quality, and boost quality of life. Fri, 31 Jan 2025 11:07:04 EST https://www.sciencedaily.com/releases/2025/01/250131110704.htm https://www.sciencedaily.com/releases/2025/01/250110121922.htm The in-built in protection mechanisms offer a safer and more effective way to combat the deadliest disease of 2024. Fri, 10 Jan 2025 12:19:22 EST https://www.sciencedaily.com/releases/2025/01/250110121922.htm https://www.sciencedaily.com/releases/2024/12/241223135334.htm A year after becoming available, vaccines to protect against RSV in newborns and older adults are being more widely accepted by the American public, according to a new health survey. Mon, 23 Dec 2024 13:53:34 EST https://www.sciencedaily.com/releases/2024/12/241223135334.htm https://www.sciencedaily.com/releases/2024/12/241219151655.htm Stitching together four molecules found in the standard flu vaccine ensures an immune response to all of them, scientists have shown. Thu, 19 Dec 2024 15:16:55 EST https://www.sciencedaily.com/releases/2024/12/241219151655.htm https://www.sciencedaily.com/releases/2024/12/241218132122.htm A live-attenuated vaccine under development is safe and 100% effective against Lassa virus in preclinical studies. Wed, 18 Dec 2024 13:21:22 EST https://www.sciencedaily.com/releases/2024/12/241218132122.htm https://www.sciencedaily.com/releases/2024/12/241210114948.htm Research shows that HPV accounts for 70% of all throat cancers, but only one-third of the public is aware that HPV causes throat cancer. Tue, 10 Dec 2024 11:49:48 EST https://www.sciencedaily.com/releases/2024/12/241210114948.htm https://www.sciencedaily.com/releases/2024/12/241209122950.htm Researchers found that transmission of rotavirus vaccine strains in a neonatal intensive care unit (NICU) is rare and without clinical consequences, strongly suggesting that giving the rotavirus vaccine to eligible infants during their hospitalization provides immune benefits that outweigh any risks. The findings could serve as the basis for a change in clinical practice. Mon, 09 Dec 2024 12:29:50 EST https://www.sciencedaily.com/releases/2024/12/241209122950.htm https://www.sciencedaily.com/releases/2024/11/241119132314.htm In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can cause severe pneumonia and even death. Vaccines against both viruses, however, have been difficult to design. Now, scientists have analyzed the structure and stability of a critical RSV and hMPV protein to better design vaccines that target it. Tue, 19 Nov 2024 13:23:14 EST https://www.sciencedaily.com/releases/2024/11/241119132314.htm https://www.sciencedaily.com/releases/2024/11/241113123430.htm An FDA-approved vaccine for smallpox and mpox is effective but causes side effects. The other requires multiple doses. An experimental single-dose vaccine uses the horsepox virus to harness the benefits of both strategies. Wed, 13 Nov 2024 12:34:30 EST https://www.sciencedaily.com/releases/2024/11/241113123430.htm https://www.sciencedaily.com/releases/2024/10/241017112707.htm A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff. In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile first-time infections and relapsing infections by inducing a robust immune response, promote clearance of existing C. diff bacteria from the gut, and even overcome deficits in host immunity to protect animals after infection, according to researchers. The results will pave the way for clinical trials of the vaccine. Thu, 17 Oct 2024 11:27:07 EDT https://www.sciencedaily.com/releases/2024/10/241017112707.htm https://www.sciencedaily.com/releases/2024/10/241016120026.htm A new study has provided a detailed analysis of how mRNA vaccines circulate and break down in the human bloodstream. The research aimed to help improve the safety and effectiveness of these vaccines, including reducing the side effects that people commonly experience such as headaches, fever and fatigue. Wed, 16 Oct 2024 12:00:26 EDT https://www.sciencedaily.com/releases/2024/10/241016120026.htm https://www.sciencedaily.com/releases/2024/09/240920160801.htm Researchers have shown that they can generate a strong immune response against HIV with two doses of a vaccine given one week apart. Fri, 20 Sep 2024 16:08:01 EDT https://www.sciencedaily.com/releases/2024/09/240920160801.htm https://www.sciencedaily.com/releases/2024/09/240919174748.htm Syphilis cases have surged worldwide, leaving public health officials scrounging for ways to stop the spread. Now, a large, collaborative study of syphilis genetics from four continents has found hints of a possible target for a vaccine. Thu, 19 Sep 2024 17:47:48 EDT https://www.sciencedaily.com/releases/2024/09/240919174748.htm https://www.sciencedaily.com/releases/2024/09/240912135656.htm A promising Lassa fever vaccine shows potential to prevent severe disease and death in animals. Thu, 12 Sep 2024 13:56:56 EDT https://www.sciencedaily.com/releases/2024/09/240912135656.htm https://www.sciencedaily.com/releases/2024/09/240904130825.htm The most frequently used mpox vaccine provides partial immunity to the disease but isn't always able to prevent severe symptoms or disease transmission. A new vaccine candidate from Moderna, mRNA-1769, more effectively limits symptoms and disease duration in primates that were infected with a lethal strain of the mpox virus when compared to a currently licensed modified vaccinia Ankara (MVA) vaccine. Wed, 04 Sep 2024 13:08:25 EDT https://www.sciencedaily.com/releases/2024/09/240904130825.htm https://www.sciencedaily.com/releases/2024/08/240827105013.htm A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic. Tue, 27 Aug 2024 10:50:13 EDT https://www.sciencedaily.com/releases/2024/08/240827105013.htm https://www.sciencedaily.com/releases/2024/08/240826182929.htm Certain types of gut bacteria can hinder the efficacy of the rotavirus vaccine, according to researchers. Mon, 26 Aug 2024 18:29:29 EDT https://www.sciencedaily.com/releases/2024/08/240826182929.htm https://www.sciencedaily.com/releases/2024/08/240820124435.htm Scientists have discovered why the flu vaccine can perform poorly. They found that a specific type of immune cell, called T follicular helper cells, indirectly controls the anti-influenza response. These helper cells often 'see' the wrong parts of the virus, likely leading to immunity that is less effective. Tue, 20 Aug 2024 12:44:35 EDT https://www.sciencedaily.com/releases/2024/08/240820124435.htm https://www.sciencedaily.com/releases/2024/08/240815163616.htm A unique influenza vaccine candidate that's inhaled appears safe and could bolster protection against seasonal and pandemic influenza for people vulnerable to severe disease when they receive it in addition to the annual flu shot. Thu, 15 Aug 2024 16:36:16 EDT https://www.sciencedaily.com/releases/2024/08/240815163616.htm https://www.sciencedaily.com/releases/2024/08/240814185758.htm Recent trials of an experimental malaria vaccine in healthy Malian adults found that all three tested regimens were safe. One of the trials enrolled 300 healthy women ages 18 to 38 years who anticipated becoming pregnant soon after immunization. That trial began with drug treatment to remove malaria parasites, followed by three injections spaced over a month of either saline placebo or the investigational vaccine at one of two dosages. Wed, 14 Aug 2024 18:57:58 EDT https://www.sciencedaily.com/releases/2024/08/240814185758.htm https://www.sciencedaily.com/releases/2024/08/240814124546.htm A vaccine against cancer-causing human papillomaviruses (HPV) is intended to help increase the rate of HPV vaccinations, particularly in developing countries. Scientists developed a completely new vaccination concept for this purpose. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections. Wed, 14 Aug 2024 12:45:46 EDT https://www.sciencedaily.com/releases/2024/08/240814124546.htm https://www.sciencedaily.com/releases/2024/08/240809135948.htm A new, two-step flu vaccination strategy that pairs intramuscular injection of a viral vectored flu vaccine with nasal spray administration of a novel attenuated live flu virus appears to be safe and effective in pigs, researchers report. Fri, 09 Aug 2024 13:59:48 EDT https://www.sciencedaily.com/releases/2024/08/240809135948.htm https://www.sciencedaily.com/releases/2024/07/240731170756.htm A nasal COVID-19 vaccine blocks transmission of the virus, according to an animal study. The findings suggest that vaccines delivered directly to the nose or mouth could play a critical role in containing the spread of respiratory infections. Wed, 31 Jul 2024 17:07:56 EDT https://www.sciencedaily.com/releases/2024/07/240731170756.htm https://www.sciencedaily.com/releases/2024/07/240719123816.htm New research reveals a promising approach to developing a universal influenza vaccine -- a so-called 'one and done' vaccine that confers lifetime immunity against an evolving virus. The study tested a vaccine platform against the virus considered most likely to trigger the next pandemic. Fri, 19 Jul 2024 12:38:16 EDT https://www.sciencedaily.com/releases/2024/07/240719123816.htm https://www.sciencedaily.com/releases/2024/07/240702161514.htm A major challenge in developing a vaccine for HIV is that the virus mutates fast -- very fast. Although a person initially becomes infected with one or a few HIV strains, the virus replicates and mutates quickly, resulting in a 'swarm' of viral strains existing in a single body. Tue, 02 Jul 2024 16:15:14 EDT https://www.sciencedaily.com/releases/2024/07/240702161514.htm https://www.sciencedaily.com/releases/2024/06/240619143640.htm Tuberculosis is a serious health threat, and the efficacy of the BCG vaccine against tuberculosis diminishes in adulthood, making booster vaccines a realistic option. Mycobacterial DNA-binding protein 1 (MDP1), a protein found in Mycobacterium tuberculosis, elicits higher protective IFN-gamma responses in individuals who suppress tuberculosis, thus making it a vaccine candidate. Wed, 19 Jun 2024 14:36:40 EDT https://www.sciencedaily.com/releases/2024/06/240619143640.htm https://www.sciencedaily.com/releases/2024/05/240522130506.htm Researchers conducted a Phase III trial to test the 100-year-old Bacillus Calmette-Gu rin (BCG) vaccine in people with type 1 diabetes during the COVID-19 pandemic. Wed, 22 May 2024 13:05:06 EDT https://www.sciencedaily.com/releases/2024/05/240522130506.htm https://www.sciencedaily.com/releases/2024/05/240517164126.htm A study has found that repeat vaccination with updated versions of the COVID-19 vaccine promotes the development of antibodies that neutralize a wide range of variants of the virus that causes COVID-19, as well as related coronaviruses. Fri, 17 May 2024 16:41:26 EDT https://www.sciencedaily.com/releases/2024/05/240517164126.htm https://www.sciencedaily.com/releases/2024/05/240517111457.htm An HIV vaccine candidate triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial. Fri, 17 May 2024 11:14:57 EDT https://www.sciencedaily.com/releases/2024/05/240517111457.htm